Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Allison A Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer, Rick Doblin, Allison A Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer, Rick Doblin

Abstract

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment of PTSD on the basis of pooled analyses showing a large effect size for this treatment. This review covers data supporting BTD. In this treatment, MDMA is administered with psychotherapy in up to three monthly 8-h sessions. Participants are prepared for these sessions beforehand, and process material arising from the sessions in follow-up integrative psychotherapy sessions. Comparing data used for the approval of paroxetine and sertraline and pooled data from Phase 2 studies, MAPS demonstrated that MDMA-assisted psychotherapy constitutes a substantial improvement over available pharmacotherapies in terms of safety and efficacy. Studies of MDMA-assisted psychotherapy had lower dropout rates compared to sertraline and paroxetine trials. As MDMA is only administered under direct observation during a limited number of sessions, there is little chance of diversion, accidental or intentional overdose, or withdrawal symptoms upon discontinuation. BTD status has expedited the development of MAPS phase 3 trials occurring worldwide, leading up to a planned submission seeking FDA approval in 2021. Clinical Trial Registration: www.ClinicalTrials.gov, identifiers NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.

Keywords: anxiety; breakthrough therapy; methylenedioxymethamphetamine; paroxetine; posttraumatic stress disorder; sertraline.

Copyright © 2019 Feduccia, Jerome, Yazar-Klosinski, Emerson, Mithoefer and Doblin.

References

    1. Food and Drug Administration Guidance for industry; expedited programs for serious conditions — drugs and biologics. Silver Spring, MD: US Dept. of Health and Human Services; (2014).
    1. Food and Drug Administration CDER breakthrough therapy designation requests received by fiscal year. (2018). ”. Food and Drug Administration).
    1. Haviland MG, Banta JE, Sonne JL, Przekop P. Posttraumatic stress disorder-related hospitalizations in the United States (2002–2011): rates, co-occurring illnesses, suicidal ideation/self-harm, and hospital charges. J Nerv Ment Dis (2016) 204:78–86. 10.1097/NMD.0000000000000432
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 62:593–602. 10.1001/archpsyc.62.6.593
    1. Hoge CW, Castro CA, Messer SC, Mcgurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med (2004) 351:13–22. 10.1056/NEJMoa040603
    1. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA (2000) 283:1837–44. 10.1001/jama.283.14.1837
    1. Davidson JR, Rothbaum BO, Van Der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry (2001) 58:485–92. 10.1001/archpsyc.58.5.485
    1. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry (2007) 68:711–20. 10.4088/JCP.v68n0508
    1. Foa EB, Keane TM, Friedman MJ, Cohen JA. Effective treatments for PTSD. In: Practice guidelines from the International Society for Traumatic Stress Studies. Guilford Press; (2009).
    1. Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev (2010) 30:635–41. 10.1016/j.cpr.2010.04.007
    1. Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA (2015) 314:489–500. 10.1001/jama.2015.8370
    1. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety (2016) 33:792–806. 10.1002/da.22511
    1. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry (2015) 206:93–100. 10.1192/bjp.bp.114.148551
    1. Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med (2018) 48:1975–84. 10.1017/S003329171700349X
    1. Mott JM, Mondragon S, Hundt NE, Beason-Smith M, Grady RH, Teng EJ. Characteristics of U.S. veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD. J Trauma Stress (2014) 27:265– 73. 10.1002/jts.21927
    1. Goetter EM, Bui E, Ojserkis RA, Zakarian RJ, Brendel RW, Simon NM. A systematic review of dropout from psychotherapy for posttraumatic stress disorder among Iraq and Afghanistan combat veterans. J Trauma Stress (2015) 28:401–9. 10.1002/jts.22038
    1. Pfizer Zoloft (sertraline) New Drug Application (NDA). 235 E. 42nd St., New York, NY: Pfizer; (1999). .
    1. Glaxosmithkline Paxil (paroxetine). Package insert. Brentwood, London, UK: GlaxoSmithKline; (2001. c). .
    1. Glaxosmithkline Paxil (paroxetine) approval letter and package insert. Brentwood, London, UK: GlaxoSmithKline; (2001. b). .
    1. Pfizer Zoloft (sertraline) package label. New York NY: Pfizer; (2009). .
    1. O’neil MJ. The Merck index: an encyclopedia of chemicals, drugs, and biologicals. 15th edition Whitehouse Station, NJ: RSC Publishing; (2013).
    1. Feduccia AA, Holland J, Mithoefer MC. Progress and promise for the MDMA drug development program. Psychopharmacology (Berl) (2018) 235:561–71. 10.1007/s00213-017-4779-2
    1. Thompson MR, Hunt GE, Mcgregor IS. Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats. Soc Neurosci (2009) 4:60–72. 10.1080/17470910802045042
    1. Curry DW, Berro LF, Belkoff AR, Sulima A, Rice KC, Howell LL. Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA). Neuropharmacology (2019) 151:13–20. 10.1016/j.neuropharm.2019.03.017
    1. Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature (2019) 569 (7754):116–20. 10.1038/s41586-019-1075-9
    1. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res (1996) 73:103–7. 10.1016/0166-4328(96)00078-2
    1. Dumont GJ, Sweep FC, Van Der Steen R, Hermsen R, Donders AR, Touw DJ, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci (2009) 4:359–66. 10.1080/17470910802649470
    1. Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab (2011) 96:2844–50. 10.1210/jc.2011-1143
    1. Hysek CM, Domes G, Liechti ME. MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology (Berl) (2012) 222:293–302. 10.1007/s00213-012-2645-9
    1. Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol (2014) 17:527–40. 10.1017/S1461145713001405
    1. Frye CG, Wardle MC, Norman GJ, De Wit H. MDMA decreases the effects of simulated social rejection. Pharmacol Biochem Behav (2014) 117:1–6. 10.1016/j.pbb.2013.11.030
    1. Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci (2014) 9:1645–52. 10.1093/scan/nst161
    1. Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME, Hysek CM, et al. MDMA effects consistent across laboratories. Psychopharmacology (Berl) (2014) 231:3899–905. 10.1007/s00213-014-3528-z
    1. Bershad AK, Miller MA, Baggott MJ, De Wit H. The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants? J Psychopharmacol (2016) 30:1248–58. 10.1177/0269881116663120
    1. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology (2000) 23:388–95. 10.1016/S0893-133X(00)00130-5
    1. Bedi G, Phan KL, Angstadt M, De Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) (2009) 207:73–83. 10.1007/s00213-009-1635-z
    1. Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, et al. The Effects of Acutely Administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry (2015) 78:554–62. 10.1016/j.biopsych.2013.12.015
    1. Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry (2016) 3 (5):481–88. 10.1016/S2215-0366(15)00576-3
    1. Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry (2018) 84:221–8. 10.1016/j.pnpbp.2018.03.003
    1. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (2011) 25:439–52. 10.1177/0269881110378371
    1. Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (+/− 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol (2013) 27:40–52. 10.1177/0269881112464827
    1. Mithoefer M. (2017). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder; Version 8, Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies.
    1. Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry (2018) 5:486–97. 10.1016/S2215-0366(18)30135-4
    1. Ot’alora GM, Grigsby J, Poulter B, Van Derveer JW, Giron SG, Jerome L, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol (2018) 32:1295–307. 10.1177/0269881118806297
    1. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol (2013) 27:28–39. 10.1177/0269881112456611
    1. Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl) (2018) 235(11):3137–48. 10.1007/s00213-018-5010-9.
    1. Mithoefer MC, Wagner MT, Mithoefer AT, Martin S, Jerome L, Michel Y, et al. Safety, Efficacy and Durability of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: completed and ongoing randomized, controlled, triple-blind phase 2 pilot studies. In: Military medical research across the continuum of care., Fort Lauderdale, FL Military medical research accross the continuum.(2012).
    1. Mithoefer M, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for Phase 3 trials based on pooled analysis of six Phase 2 randomized controlled trials. Psychopharmacology (Berl) (2019) 236 (9):2735–45. 10.1007/s00213-019-05249-5
    1. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminzer G, Charney DS, et al. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behav Ther (1990) 13:187–8.
    1. Weathers FW. Clinician-Administered PTSD Scale (CAPS): Technical Manual. Los Angeles, CA: Western Psychological Services; (2004).
    1. GlaxoSmithKline New Drug Application (NDA 20-031/S-029) Paxil (Paroxetine Hydrochloride) Tablets. Posttraumatic stress disorder. (2001. a). , Food and Drug Administration.
    1. Keller SM, Zoellner LA, Feeny NC. Understanding factors associated with early therapeutic alliance in PTSD treatment: adherence, childhood sexual abuse history, and social support. J Consult Clin Psychol (2010) 78:974–9. 10.1037/a0020758
    1. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) (2001) 154:161–8. 10.1007/s002130000648
    1. Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol (2017) 31:576–88. 10.1177/0269881117691569
    1. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom (2015) 84:72–81. 10.1159/000370338
    1. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci (1999) 19:10494–501. 10.1523/JNEUROSCI.19-23-10494.1999
    1. Jager G, De Win MM, Vervaeke HK, Schilt T, Kahn RS, Van Den Brink W, et al. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology (Berl) (2007) 193:403–14. 10.1007/s00213-007-0792-1
    1. Schilt T, De Win MM, Koeter M, Jager G, Korf DJ, Van Den Brink W, et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry (2007) 64:728–36. 10.1001/archpsyc.64.6.728
    1. Kuypers KPC, Theunissen EL, Van Wel JHP, De Sousa Fernandes Perna EB, Linssen A, Sambeth A, et al. Verbal memory impairment in polydrug Ecstasy users: a clinical perspective. PLoS One (2016) 11:e0149438. 10.1371/journal.pone.0149438
    1. Szigeti B, Winstock AR, Erritzoe D, Maier LJ. Are ecstasy induced serotonergic alterations overestimated for the majority of users? J Psychopharmacol (2018) 32:741–8. 10.1177/0269881118767646
    1. Amoroso T. The spurious relationship between ecstasy use and neurocognitive deficits: a Bradford Hill review. Int J Drug Policy (2019) 64:47–53. 10.1016/j.drugpo.2018.11.002
    1. Multidisciplinary Association for Psychedelic Studies Investigator’s brochure: 3,4-methylenedioxymethamphetamine (MDMA), 11th edition, (2019). ”.
    1. Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL. 2015 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila) (2016) 54:924–1109. 10.1080/15563650.2016.1245421
    1. Mcdevitt-Murphy ME, Williams JL, Bracken KL, Fields JA, Monahan CJ, Murphy JG. PTSD symptoms, hazardous drinking, and health functioning among U.S.OEF and OIF veterans presenting to primary care. J Trauma Stress (2010) 23:108–11. 10.1002/jts.20482
    1. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord (2011) 25:456–65. 10.1016/j.janxdis.2010.11.010
    1. Merz J, Schwarzer G, Gerger H. Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. JAMA Psychiatry (2019) . 10.1001/jamapsychiatry.2019.0951
    1. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep (2018) 23:3170–82. 10.1016/j.celrep.2018.05.022
    1. Wagner MT, Mithoefer MC, Mithoefer AT, Macaulay RK, Jerome L, Yazar-Klosinski B, et al. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol (2017) 31:967–74. 10.1177/0269881117711712
    1. Mchugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry (2013) 74:595–602. 10.4088/JCP.12r07757
    1. Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl) (2018) 235:467–79. 10.1007/s00213-017-4650-5

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren